Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.8
Journals
Pharmaceuticals
Special Issues
The Therapeutic Potential of Cannabidiol
share announcement

The Therapeutic Potential of Cannabidiol

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 25 November 2025 | Viewed by 849

Special Issue Editors

Dr. Karolina Walczyńska-Dragon

E-Mail Website
Guest Editor
Department of Temporomandibular Disorders, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland
Interests: temporomandibular disorders; bruxism; cannabidiol; orofacial pain; muscle relaxation; pain modulation
Special Issues, Collections and Topics in MDPI journals
Dr. Anna Kurek-Górecka

E-Mail Website
Guest Editor
Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana Street, 41-800 Zabrze, Poland
Interests: cytokines; immunology; natural products; apitherapy; oral cavity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa, has recently attracted significant attention in both clinical and basic science communities due to its potential therapeutic benefits. Evidence suggests that CBD may offer promising effects in pain modulation, muscle relaxation, neuroprotection, and the management of inflammation—without the psychotropic effects associated with THC.

This Special Issue aims to explore and consolidate current research on the therapeutic properties of cannabidiol, with a particular focus on its application in conditions such as orofacial pain, temporomandibular disorders, bruxism, and neuromuscular dysfunction. We invite original research papers, clinical trials, systematic reviews, and short communications that investigate the efficacy, mechanisms of action, safety profile, pharmacological properties, and pharmaceutical formulations of CBD.

We also encourage submissions that examine interdisciplinary or biopsychosocial approaches incorporating cannabidiol as part of a broader therapeutic strategy.

We look forward to your valuable contributions to this timely and rapidly developing field.

Dr. Karolina Walczyńska-Dragon
Dr. Anna Kurek-Górecka
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cannabidiol
  • endocannabinoid system
  • pain
  • anti-inflammatory agents
  • muscle spasticity
  • pain management
  • chronic pain

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1206 KiB  
Article
Expanding the Therapeutic Profile of Topical Cannabidiol in Temporomandibular Disorders: Effects on Sleep Quality and Migraine Disability in Patients with Bruxism-Associated Muscle Pain
by Karolina Walczyńska-Dragon, Jakub Fiegler-Rudol, Stefan Baron and Aleksandra Nitecka-Buchta
Pharmaceuticals 2025, 18(7), 1064; https://doi.org/10.3390/ph18071064 - 19 Jul 2025
Viewed by 150
Abstract
Background: Cannabidiol (CBD) has demonstrated potential as a therapeutic agent for muscle tension, pain, and sleep bruxism, yet its broader impact on comorbid conditions such as sleep disturbance and migraine disability remains underexplored. This study aimed to assess the effects of topical [...] Read more.
Background: Cannabidiol (CBD) has demonstrated potential as a therapeutic agent for muscle tension, pain, and sleep bruxism, yet its broader impact on comorbid conditions such as sleep disturbance and migraine disability remains underexplored. This study aimed to assess the effects of topical CBD on sleep quality and migraine-related disability in patients with bruxism-associated muscular pain. Methods: In a randomized, double-blind clinical trial, 60 participants with bruxism were allocated equally into three groups: control (placebo gel), 5% CBD gel, and 10% CBD gel. Participants applied the gel intraorally to the masseter muscles nightly for 30 days. Sleep quality and migraine-related disability were assessed using the Pittsburgh Sleep Quality Index (PSQI) and the Migraine Disability Assessment Scale (MIDAS), respectively. Surface electromyography (sEMG) and the Bruxoff® device were used for objective evaluation of muscle tension and bruxism intensity. Results: Both CBD treatment groups demonstrated statistically significant improvements in PSQI and MIDAS scores compared to the control group (p < 0.001). No significant differences were observed between the 5% and 10% CBD groups, suggesting comparable efficacy. The sEMG findings corroborated a reduction in muscle tension. Improvements in sleep and migraine outcomes were positively correlated with reductions in muscle activity and pain. Conclusions: Topical CBD gel significantly improved sleep quality and reduced migraine-related disability in patients with bruxism-associated muscular pain, supporting its role as a multifaceted therapeutic option in the management of TMD and related comorbidities. Further research is needed to confirm long-term benefits and determine optimal dosing strategies. Full article
(This article belongs to the Special Issue The Therapeutic Potential of Cannabidiol)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop